Wall Street analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to report ($0.57) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for IDEAYA Biosciences’ earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.63). IDEAYA Biosciences reported earnings of ($1.30) per share in the same quarter last year, which indicates a positive year over year growth rate of 56.2%. The business is scheduled to report its next quarterly earnings report on Monday, August 10th.
On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($2.53) to $2.30. For the next financial year, analysts expect that the business will post earnings of ($1.89) per share, with EPS estimates ranging from ($3.08) to $0.25. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for IDEAYA Biosciences.
IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.02).
Several analysts have issued reports on IDYA shares. Zacks Investment Research downgraded shares of IDEAYA Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 26th. BidaskClub upgraded shares of IDEAYA Biosciences from a “buy” rating to a “strong-buy” rating in a report on Friday. Roth Capital assumed coverage on shares of IDEAYA Biosciences in a report on Friday, March 13th. They issued a “buy” rating and a $12.00 price objective for the company. HC Wainwright boosted their target price on shares of IDEAYA Biosciences from $13.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Finally, ValuEngine raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. IDEAYA Biosciences currently has a consensus rating of “Buy” and a consensus target price of $19.45.
In other IDEAYA Biosciences news, CFO Paul A. Stone sold 3,100 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $17.97, for a total transaction of $55,707.00. Following the sale, the chief financial officer now directly owns 18,100 shares of the company’s stock, valued at $325,257. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Value Fund L. P. Biotechnology acquired 117,996 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $14.31 per share, for a total transaction of $1,688,522.76. Over the last ninety days, insiders have acquired 235,992 shares of company stock worth $3,377,408 and have sold 13,273 shares worth $190,783.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of IDEAYA Biosciences by 234.0% during the first quarter. BlackRock Inc. now owns 38,218 shares of the company’s stock valued at $158,000 after purchasing an additional 26,774 shares during the last quarter. Alambic Investment Management L.P. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $148,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $151,000. 49.87% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ IDYA traded up $0.96 during trading on Thursday, hitting $14.21. The company had a trading volume of 520,493 shares, compared to its average volume of 588,267. The company has a market cap of $294.16 million and a P/E ratio of -4.72. IDEAYA Biosciences has a 52 week low of $2.95 and a 52 week high of $19.97. The business’s 50-day moving average is $9.78 and its 200 day moving average is $7.47. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.18 and a current ratio of 12.18.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Featured Article: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.